Zhuolin Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zhuolin Zhou has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Cheng Ji
Department of Pharmacy, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China
2 shared publications - Haixia Zhang
Department of Pharmacy, Nanjing Drum Tower Hospital, Clinical College of Nanjing University of Chinese Medicine
1 shared publication - Jiaojiao Liu
Department of Pharmacy Nanjing Drum Tower Hospital, Dalian Medical University Nanjing China
1 shared publication - Nan Gao
Department of Pharmacy, Nanjing Drum Tower Hospital, China Pharmaceutical University, Nanjing, China, cpu.edu.cn
1 shared publication Xiaotian Du
University of International Business and Economics, Beijing, 100029, China, uibe.edu.cn
1 shared publicationXuerong Ma
Department of Pharmacy Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University Nanjing China
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in International Journal of Endocrinology
- Vol. 2026 (1)
Research on a Predictive Model for Microalbuminuria in Type 2 Diabetes Based on Machine Learning and SHAP Analysis
Background: Type 2 diabetes mellitus (T2DM) is associated with kidney damage, with microalbuminuria (MAU) serving as an early marker indicating the risk of progression to severe renal and cardiovascular complications, and there is an urgent need for effective prediction tools to identify MAU risk in T2DM patients and prevent adverse outcomes. This study aims to develop a machine learning–based model to enhance the early identification of high‐risk individuals and facilitate timely, personalized interventions. Methods: The electronic medical records of 4170 patients were retrospectively extracted from the diabetes special database of Nanjing Drum Tower Hospital (Ethics approval number: 2021‐403‐02). The data were divided into training and testing sets (8:2 ratio), and random forest–based recursive feature elimination method was employed to identify the most pertinent input variables for the predictive model. Five machine learning models were applied to predict the progression to MAU. The Shapley additive explanations (SHAP) values were applied for model interpretation to assess feature contributions. Ten features were selected for the construction of a prediction model. Results: For predicting the progression to MAU, the Light GBM model demonstrated the best performance (AUC 0.85, 95% CI 0.82–0.88). By analyzing the Shapley values of the model outputs, we identified the key risk factors for predicting the diagnosis of MAU at both the cohort and individual levels. Conclusions: This study developed an interpretable machine learning model to predict MAU in T2DM patients, enabling effective risk stratification and identification of high‐risk individuals based on baseline data to guide personalized clinical interventions and optimization of treatment.
- 1 January 2026
- Published by Wiley in International Journal of Endocrinology
- Vol. 2026 (1)
Open AccessResearch on a Predictive Model for Microalbuminuria in Type 2 Diabetes Based on Machine Learning and SHAP Analysis
Background: Type 2 diabetes mellitus (T2DM) is associated with kidney damage, with microalbuminuria (MAU) serving as an early marker indicating the risk of progression to severe renal and cardiovascular complications, and there is an urgent need for effective prediction tools to identify MAU risk in T2DM patients and prevent adverse outcomes. This study aims to develop a machine learning–based model to enhance the early identification of high‐risk individuals and facilitate timely, personalized interventions. Methods: The electronic medical records of 4170 patients were retrospectively extracted from the diabetes special database of Nanjing Drum Tower Hospital (Ethics approval number: 2021‐403‐02). The data were divided into training and testing sets (8:2 ratio), and random forest–based recursive feature elimination method was employed to identify the most pertinent input variables for the predictive model. Five machine learning models were applied to predict the progression to MAU. The Shapley additive explanations (SHAP) values were applied for model interpretation to assess feature contributions. Ten features were selected for the construction of a prediction model. Results: For predicting the progression to MAU, the Light GBM model demonstrated the best performance (AUC 0.85, 95% CI 0.82–0.88). By analyzing the Shapley values of the model outputs, we identified the key risk factors for predicting the diagnosis of MAU at both the cohort and individual levels. Conclusions: This study developed an interpretable machine learning model to predict MAU in T2DM patients, enabling effective risk stratification and identification of high‐risk individuals based on baseline data to guide personalized clinical interventions and optimization of treatment.
- Open Access
- 29 September 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (1) , 122-136
An interpretable machine learning model for predicting metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes
Aim: Patients with type 2 diabetes mellitus (T2DM) exhibit an elevated prevalence of metabolic dysfunction‐associated steatotic liver disease (MASLD) and are at greater risk of liver‐related adverse events. Existing non‐invasive tools show limited diagnostic performance in this population. This study aims to develop a predictive model that accurately identifies the risk of MASLD among T2DM patients. Materials and methods: Clinical data were collected from T2DM patients hospitalised at Nanjing Drum Tower Hospital between January 2018 and May 2025. Eight machine learning methods were developed to predict the risk of MASLD in T2DM patients. The discriminatory ability of the models was evaluated using area under the receiver operating characteristic curve (AUROC), area under the precision‐recall curve (AUPRC), accuracy, recall, negative predictive value, positive predictive value, and F1 score. Calibration curves and decision analysis curves were employed to evaluate the calibration and clinical utility. The models were interpreted using the Shapley additive explanations method, and unsupervised clustering was performed to identify potential high‐risk subgroups. Results: A total of 3836 T2DM patients constituted the complete dataset, with a MASLD incidence rate of 55.9%. Thirteen feature variables were selected for model construction, and the XGB model achieved optimal overall performance, with an AUROC of 0.873 and an AUPRC of 0.904. Unsupervised clustering identified several high‐risk subgroups with distinct metabolic characteristics. Conclusion: The model developed enables reliable and interpretable MASLD risk prediction in T2DM patients based on selected commonly available clinical data, providing a practical tool for routine identification and stratified management.
- 29 September 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (1) , 122-136
Open AccessAn interpretable machine learning model for predicting metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes
Aim: Patients with type 2 diabetes mellitus (T2DM) exhibit an elevated prevalence of metabolic dysfunction‐associated steatotic liver disease (MASLD) and are at greater risk of liver‐related adverse events. Existing non‐invasive tools show limited diagnostic performance in this population. This study aims to develop a predictive model that accurately identifies the risk of MASLD among T2DM patients. Materials and methods: Clinical data were collected from T2DM patients hospitalised at Nanjing Drum Tower Hospital between January 2018 and May 2025. Eight machine learning methods were developed to predict the risk of MASLD in T2DM patients. The discriminatory ability of the models was evaluated using area under the receiver operating characteristic curve (AUROC), area under the precision‐recall curve (AUPRC), accuracy, recall, negative predictive value, positive predictive value, and F1 score. Calibration curves and decision analysis curves were employed to evaluate the calibration and clinical utility. The models were interpreted using the Shapley additive explanations method, and unsupervised clustering was performed to identify potential high‐risk subgroups. Results: A total of 3836 T2DM patients constituted the complete dataset, with a MASLD incidence rate of 55.9%. Thirteen feature variables were selected for model construction, and the XGB model achieved optimal overall performance, with an AUROC of 0.873 and an AUPRC of 0.904. Unsupervised clustering identified several high‐risk subgroups with distinct metabolic characteristics. Conclusion: The model developed enables reliable and interpretable MASLD risk prediction in T2DM patients based on selected commonly available clinical data, providing a practical tool for routine identification and stratified management.